These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35973601)

  • 21. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.
    Breeksema JJ; Kuin BW; Kamphuis J; van den Brink W; Vermetten E; Schoevers RA
    J Psychopharmacol; 2022 Oct; 36(10):1100-1117. PubMed ID: 36017784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Past Is Prologue: Ethical Issues in Pediatric Psychedelics Research and Treatment.
    Edelsohn GA; Sisti D
    Perspect Biol Med; 2023; 66(1):129-144. PubMed ID: 38662012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality.
    Jones GM; Nock MK
    Sci Rep; 2022 Oct; 12(1):16976. PubMed ID: 36216840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes.
    Jones GM
    J Psychopharmacol; 2023 Jan; 37(1):61-69. PubMed ID: 36314881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer.
    Barnett BS; Greer GR
    J Acad Consult Liaison Psychiatry; 2021; 62(4):460-471. PubMed ID: 34210406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Why Otolaryngologists Should Be Interested in Psychedelic Medicine.
    Asher BF
    Otolaryngol Clin North Am; 2022 Oct; 55(5):929-938. PubMed ID: 36088153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Psychedelics: Threshold of a Therapeutic Revolution.
    Heal DJ; Smith SL; Belouin SJ; Henningfield JE
    Neuropharmacology; 2023 Sep; 236():109610. PubMed ID: 37247807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The varieties of psychedelic law.
    Marks M
    Neuropharmacology; 2023 Mar; 226():109399. PubMed ID: 36565855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A taxonomy of regulatory and policy matters relevant to psychedelic-assisted therapy in Australia.
    Hatfield SP; Thornton NL; Greenstien K; Glozier N
    Aust N Z J Psychiatry; 2024 Jul; 58(7):571-590. PubMed ID: 38628079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Valuing the Acute Subjective Experience.
    Cheung K; Earp BD; Yaden DB
    Perspect Biol Med; 2024; 67(1):155-165. PubMed ID: 38662070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strong Bipartisan Support for Controlled Psilocybin Use as Treatment or Enhancement in a Representative Sample of US Americans: Need for Caution in Public Policy Persists.
    Sandbrink JD; Johnson K; Gill M; Yaden DB; Savulescu J; Hannikainen IR; Earp BD
    AJOB Neurosci; 2024; 15(2):82-89. PubMed ID: 38315212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses.
    Chi T; Gold JA
    J Neurol Sci; 2020 Apr; 411():116715. PubMed ID: 32044687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expert opinions on implementation of MDMA-assisted therapy in Europe: critical appraisal towards training, clinical practice, and regulation.
    Herpers J; Maximets N; van Dongen NNN; Zijlmans J; Vermetten E
    Eur J Psychotraumatol; 2024; 15(1):2378651. PubMed ID: 39113624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic role of psilocybin and 3,4-methylenedioxymethamphetamine in trauma: A literature review.
    Fonseka LN; Woo BK
    World J Psychiatry; 2023 May; 13(5):182-190. PubMed ID: 37303932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA.
    Mithoefer MC; Grob CS; Brewerton TD
    Lancet Psychiatry; 2016 May; 3(5):481-8. PubMed ID: 27067625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.
    Dunlap LE; Andrews AM; Olson DE
    ACS Chem Neurosci; 2018 Oct; 9(10):2408-2427. PubMed ID: 30001118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review of potential psychedelic treatments for PTSD.
    Henner RL; Keshavan MS; Hill KP
    J Neurol Sci; 2022 Aug; 439():120302. PubMed ID: 35700643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies.
    Fogg C; Michaels TI; de la Salle S; Jahn ZW; Williams MT
    Exp Clin Psychopharmacol; 2021 Oct; 29(5):539-554. PubMed ID: 34096755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preferences and Support for Psychedelic Policies and Practices Among Those Using Psychedelics.
    Kruger DJ; Barron J; Herberholz M; Boehnke KF
    J Psychoactive Drugs; 2023; 55(5):650-659. PubMed ID: 37353935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].
    Majić T; Jungaberle H; Schmidt TT; Zeuch A; Hermle L; Gallinat J
    Fortschr Neurol Psychiatr; 2017 Jul; 85(7):383-392. PubMed ID: 28768346
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.